Lercanidipine-13C,d3-1 hydrochloride

发表于由

上海金畔生物科技有限公司为生命科学和医药研发人员提供生物活性分子抑制剂、激动剂、特异性抑制剂、化合物库、重组蛋白、同位素标记物，专注于信号通路和疾病研究领域。
Lercanidipine-13C,d3-1 hydrochloride 

Lercanidipine-13C,d3-1 (hydrochloride) 是 Lercanidipine (hydrochloride) 氘代物。Lercanidipine hydrochloride 是一种亲脂性的第三代二氢吡啶-钙通道阻滞剂 (DHP-CCB)。Lercanidipine hydrochloride 具有持久的降压作用和对肾脏的保护作用。

Lercanidipine-13C,d3-1 hydrochloride

Lercanidipine-13C,d3-1 hydrochloride Chemical Structure

CAS No. : 2747918-20-1

规格 是否有货
100 mg   询价  
250 mg   询价  
500 mg   询价  

* Please select Quantity before adding items.

生物活性

Lercanidipine-13C,d3-1 (hydrochloride) is deuterium labeled Lercanidipine (hydrochloride). Lercanidipine hydrochloride is a lipophilic third-generation dihydropyridine-calcium channel blocker (DHP-CCB). Lercanidipine hydrochloride has long lasting antihypertensive action and reno-protective effect[1][2][3].

体外研究
(In Vitro)

Stable heavy isotopes of hydrogen, carbon, and other elements have been incorporated into drug molecules, largely as tracers for quantitation during the drug development process. Deuteration has gained attention because of its potential to affect the pharmacokinetic and metabolic profiles of drugs[1].

Shanghai Jinpan Biotech Co Ltd has not independently confirmed the accuracy of these methods. They are for reference only.
分子量

652.20

Formula

C3513CH39D3ClN3O6
CAS 号

2747918-20-1
运输条件

Room temperature in continental US; may vary elsewhere.
储存方式

Please store the product under the recommended conditions in the Certificate of Analysis.
参考文献

  • [1]. Russak EM, et al. Impact of Deuterium Substitution on the Pharmacokinetics of Pharmaceuticals. Ann Pharmacother. 2019;53(2):211-216.

    [2]. Barrios, V., et al., Lercanidipine is an effective and well tolerated antihypertensive drug regardless the cardiovascular risk profile: The LAURA study. Int J Clin Pract, 2006. 60(11): p. 1364-70.

    [3]. Burnier, M., M. Pruijm, and G. Wuerzner, Treatment of essential hypertension with calcium channel blockers: what is the place of lercanidipine? Expert Opin Drug Metab Toxicol, 2009. 5(8): p. 981-7.

    [4]. Grassi G, et, al. Lercanidipine in the Management of Hypertension: An Update. J Pharmacol Pharmacother. Oct-Dec 2017;8(4):155-165.

所有产品仅用作科学研究或药证申报，我们不为任何个人用途提供产品和服务